3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Gliosarcoma
22
Glioblastoma
22
Brain Neoplasms
16
Glioma
10
Astrocytoma
9
Oligodendroglioma
8
Central Nervous System Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
3
Carcinoma, Non-Small-Cell Lung
3
Sarcoma
2
Salivary Gland Neoplasms
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Medulloblastoma
2
Gastrointestinal Stromal Tumors
2
Esthesioneuroblastoma, Olfactory
2
Esophageal Neoplasms
2
Ependymoma
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Stomach Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Interventions
Doxorubicin
25
Gemcitabine
16
Trabectedin
12
Ifosfamide
12
Radiotherapy
11
Docetaxel
10
Dacarbazine
8
pazopanib
7
Nivolumab
6
Specimen Handling
5
Biopsy
5
liposomal doxorubicin
4
Temozolomide
4
pembrolizumab
3
Sunitinib
3
Sorafenib
3
Radiation
3
Magnetic Resonance Spectroscopy
3
Filgrastim
3
rucaparib
2
pegfilgrastim
2
olaratumab
2
eribulin
2
durvalumab
2
cixutumumab
2
cemiplimab
2
brostallicin
2
belinostat
2
avelumab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leiomyosarcoma
×
Erlotinib Hydrochloride
×
Sarcoma
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled